News from MGB Biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 06, 2017, 04:00 ET MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic...


Sep 12, 2016, 04:00 ET MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium Difficile-associated Diarrhoea (CDAD) for MGB-BP-3

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic...


Jun 14, 2016, 04:00 ET MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...


May 19, 2016, 06:11 ET MGB Biopharma Welcomes Jim O'Neill's Final Recommendations for the World to Defeat Superbugs

MGB Biopharma, a Biopharmaceutical Company Developing a Truly Novel Class of Anti-infectives, Welcomes the Final Instalment of Lord Jim O'Neill's...


May 09, 2016, 03:00 ET MGB Biopharma's Pre-IND Meeting With FDA Provides Clear Guidelines on Further Development of Oral MGB-BP-3, a Truly Novel Antibiotic Targeting Clostridium Difficile Infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic...


Feb 15, 2016, 04:00 ET MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mechanism of AMR

New compounds designed to overcome efflux pump mediated bacterial resistance   MGB Biopharma, a biopharmaceutical company developing a truly...


Jan 12, 2015, 04:00 ET MGB Biopharma Continues to Progress its Truly Novel Anti-infectives Platform to Tackle Antibiotic Resistance in 2014

  Highlights  - In September 2014, MGB Biopharma secured £4M ($6.4M) from leading Scottish investors and Innovate UK for...


Sep 17, 2014, 04:00 ET MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development

First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade  MGB Biopharma, a...


Jun 09, 2014, 07:30 ET MGB Biopharma Receives £1.3m Grant Award from the UK's Technology Strategy Board's Biomedical Catalyst

Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile    MGB Biopharma, a biopharmaceutical...


Jun 02, 2014, 04:00 ET MGB Biopharma Expands Scientific Advisory Board (SAB) with Medical Microbiologist Dr Stephanie Dancer

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Stephanie Dancer, an internationally...


Nov 18, 2013, 04:00 ET MGB Biopharma Adds its Support to European Antibiotic Awareness Day

MGB Biopharma, one of Europe's leading biopharmaceutical companies developing truly novel anti-infectives, announces its support for...


Nov 04, 2013, 04:11 ET MGB Biopharma to Present at Bio-Europe 2013

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that CEO Dr Miroslav Ravic will present...